Acasti Pharma Stock Price, News & Analysis (NASDAQ:ACST) $2.05 -0.03 (-1.44%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$2.00▼$2.1050-Day Range$1.75▼$2.9552-Week Range$1.72▼$5.05Volume13,162 shsAverage Volume28,635 shsMarket Capitalization$19.27 millionP/E RatioN/ADividend YieldN/APrice Target$14.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Acasti Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside617.1% Upside$14.70 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.25 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.44) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.68 out of 5 starsMedical Sector92nd out of 949 stocksPharmaceutical Preparations Industry32nd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingAcasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.70, Acasti Pharma has a forecasted upside of 617.1% from its current price of $2.05.Amount of Analyst CoverageAcasti Pharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.53% of the float of Acasti Pharma has been sold short.Short Interest Ratio / Days to CoverAcasti Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acasti Pharma has recently decreased by 9.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACST. Previous Next 3.6 News and Social Media Coverage News SentimentAcasti Pharma has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acasti Pharma this week, compared to 0 articles on an average week.Search Interest4 people have searched for ACST on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Acasti Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,252,067.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.00% of the stock of Acasti Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from ($1.44) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcasti Pharma has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acasti Pharma Stock (NASDAQ:ACST)Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More ACST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACST Stock News HeadlinesNovember 13, 2023 | finance.yahoo.comAcasti Announces Second Quarter 2024 Financial Results and Business HighlightsOctober 18, 2023 | markets.businessinsider.comOptimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage TreatmentNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 4, 2023 | finance.yahoo.comAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)September 27, 2023 | seekingalpha.comAcasti announces $7.5M private placement equity fundingJuly 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)July 7, 2023 | markets.businessinsider.comAcasti Pharma: Reverse Stock Split To Become Effective July 10July 7, 2023 | finance.yahoo.comAcasti Pharma Announces 1-for-6 Reverse Stock SplitNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJuly 5, 2023 | finance.yahoo.comAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023June 23, 2023 | msn.comRecap: Acasti Pharma Q4 EarningsMay 10, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash WiselyMay 8, 2023 | finance.yahoo.comAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025April 4, 2023 | finance.yahoo.comAcasti Announces Appointment of Prashant Kohli as CEOApril 4, 2023 | finance.yahoo.comAcasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDMarch 30, 2023 | finance.yahoo.comWhen Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?March 30, 2023 | finance.yahoo.comAcasti Pharma Inc. Announces the Resignation of a DirectorMarch 13, 2023 | finance.yahoo.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeFebruary 13, 2023 | msn.comAcasti Pharma's Earnings OutlookFebruary 7, 2023 | finance.yahoo.comAcasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023January 25, 2023 | finance.yahoo.comAcasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price RuleJanuary 17, 2023 | finance.yahoo.comAcasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day PodcastJanuary 5, 2023 | finance.yahoo.comAcasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome MeasuresDecember 29, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)December 29, 2022 | finance.yahoo.comAcasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call TranscriptDecember 28, 2022 | finance.yahoo.comAcasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia TelangiectasiaDecember 22, 2022 | finance.yahoo.comAcasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)See More Headlines Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today11/29/2023Next Earnings (Estimated)2/13/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACST CUSIPN/A CIK1444192 Webwww.acastipharma.com Phone45-0686-4555Fax45-0687-2272Employees32Year FoundedN/APrice Target and Rating Average Stock Price Target$14.70 High Stock Price Target$15.00 Low Stock Price Target$14.40 Potential Upside/Downside+617.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.4091) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.77% Return on Assets-11.72% Debt Debt-to-Equity RatioN/A Current Ratio20.68 Quick Ratio20.68 Sales & Book Value Annual Sales$200,000.00 Price / Sales96.35 Cash FlowN/A Price / Cash FlowN/A Book Value$7.10 per share Price / Book0.29Miscellaneous Outstanding Shares9,400,000Free Float8,129,000Market Cap$19.27 million OptionableNot Optionable Beta1.34 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Prashant Kohli (Age 51)CEO & Director Comp: $358.41kMr. Brian D. Ford CPA (Age 64)CA, Interim Chief Financial Officer Comp: $379.35kDr. R. Loch MacDonald M.D. (Age 61)Ph.D., Member of Scientific Advisory Board & Chief Medical Officer Mr. Amresh Kumar Ph.D. (Age 43)VP of Program Management Ms. Carrie D'Andrea (Age 51)VP of Clinical Operations Key CompetitorsCatalyst BiosciencesNASDAQ:CBIOViracta TherapeuticsNASDAQ:VIRXSynlogicNASDAQ:SYBXPieris PharmaceuticalsNASDAQ:PIRSLisata TherapeuticsNASDAQ:LSTAView All CompetitorsInsidersVimal KavuruBought 676,371 shares on 9/25/2023Total: $1.25 M ($1.85/share)Donald OldsBought 381 shares on 8/31/2023Total: $781.05 ($2.05/share)View All Insider Transactions ACST Stock Analysis - Frequently Asked Questions Should I buy or sell Acasti Pharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACST shares. View ACST analyst ratings or view top-rated stocks. What is Acasti Pharma's stock price target for 2024? 2 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $14.40 to $15.00. On average, they expect the company's stock price to reach $14.70 in the next twelve months. This suggests a possible upside of 617.1% from the stock's current price. View analysts price targets for ACST or view top-rated stocks among Wall Street analysts. How have ACST shares performed in 2023? Acasti Pharma's stock was trading at $3.0060 at the beginning of the year. Since then, ACST shares have decreased by 31.8% and is now trading at $2.05. View the best growth stocks for 2023 here. Are investors shorting Acasti Pharma? Acasti Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 91,900 shares, a drop of 10.0% from the October 31st total of 102,100 shares. Based on an average daily trading volume, of 49,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are sold short. View Acasti Pharma's Short Interest. When is Acasti Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ACST earnings forecast. How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10. When did Acasti Pharma's stock split? Acasti Pharma shares reverse split before market open on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS). How do I buy shares of Acasti Pharma? Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACST) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.